Form 4: Pacira BioSciences Chief Medical Officer Jonathan Slonin Reports Acquisition of Restricted Stock Units

Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, reports the acquisition of restricted stock units that vest over four years.

Summary

• On February 1, 2025, Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, acquired 93,600 restricted stock units (RSUs).
• These RSUs vest in four equal annual installments starting February 1, 2026, contingent upon continuous service with the issuer.
• Each RSU represents the right to receive one share of Pacira BioSciences' common stock.
• Following the transaction, Slonin beneficially owns 187,043.511 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the executive's continued contribution to the company.

Positives

• The vesting schedule incentivizes continued service by the Chief Medical Officer.

Risks

• The vesting of the restricted stock units is contingent upon Jonathan Slonin's continuous service with Pacira BioSciences; any departure would impact the vesting schedule.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's financial performance or future prospects beyond the vesting schedule of the restricted stock units.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biopharmaceutical industry. It reflects standard practices for incentivizing key personnel through equity-based compensation.

Comparison to Industry Standards

• Equity compensation is a standard practice in the biopharmaceutical industry to align executive interests with shareholder value.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize restricted stock units as part of their executive compensation packages.
• The vesting schedules and amounts of RSUs are typically benchmarked against peer companies to ensure competitiveness in attracting and retaining talent.

Stakeholder Impact

• Shareholders may view the granting of restricted stock units as a positive incentive for management to drive long-term value.
• Employees may see this as a sign of the company's commitment to retaining key personnel.
• The transaction itself has minimal direct impact on customers, suppliers, or creditors.

Key Dates

Keywords

Pacira BioSciences, PCRX, Jonathan Slonin, Chief Medical Officer, Restricted Stock Units, RSU, Beneficial Ownership, Form 4, SEC